<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02959398</url>
  </required_header>
  <id_info>
    <org_study_id>P120121</org_study_id>
    <nct_id>NCT02959398</nct_id>
  </id_info>
  <brief_title>Evaluation of Tomosynthesis for Characterization and the Management of Breast Lesions</brief_title>
  <acronym>ETOLE</acronym>
  <official_title>EVALUATION DE LA TOMOSYNTHESE DANS LA CARACTERISATION ET LA PRISE EN CHARGE DES LESIONS MAMMAIRES : &quot;ETOLE&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tomosynthesis is an innovative technique developed in digital mammography for obtaining a
      sectional image of the breast. Mammography has the main disadvantage of being an imaging
      projection that creates overlays, which eliminates tomosynthesis.

      The objective of this study is to evaluate if the BI-RADS classification obtained by
      tomosynthesis with synthetic mammography is superior to that obtained by conventional
      mammography in terms of specificity while not inferior in terms of sensitivity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Breast Imaging-Reporting And Data System (BI-RADS) scale</measure>
    <time_frame>Day 1</time_frame>
    <description>The primary evaluation parameter will be the classification error of tumors according to the BiRads scale obtained by mammography (BiRadsM) and by tomosynthesis (BiRadsT) according to the gold standard.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Criteria for a poor prognosis</measure>
    <time_frame>Day 1</time_frame>
    <description>The visibility (presence or absence) of signs of poor prognosis criteria. We will compare the visibility of poor prognosis criteria seen on mammography + ultrasound and seen on tomosynthesis with synthetic mammography + ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of additional examinations</measure>
    <time_frame>Day 30</time_frame>
    <description>Needs for supplementary breast imaging exams and biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of ultrasound exams</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total radiation dose</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of the diagnostic strategies</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Agreement between readers</measure>
    <time_frame>Day 1</time_frame>
    <description>The reproducibility of the interpretation of tomosynthesis will be assessed with differences of classifications BiRadsT observed between the two radiologists</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of Breast cancer diagnosis</measure>
    <time_frame>Month 24</time_frame>
    <description>Cumulative incidence of Breast cancer diagnosis among women with benign at after primary evaluation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Tomosynthesis</condition>
  <condition>BRCA1 Protein</condition>
  <condition>BRCA2 Protein</condition>
  <arm_group>
    <arm_group_label>standard mammography</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard mammography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard mammography and tomosynthesis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard mammography and tomosynthesis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard mammography</intervention_name>
    <description>Standard mammography</description>
    <arm_group_label>standard mammography</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard mammography and tomosynthesis</intervention_name>
    <description>Standard mammography and tomosynthesis</description>
    <arm_group_label>standard mammography and tomosynthesis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient having clinical or breast imaging abnormalities classified as BiRads 3, 4, 5
             (Table 1). (5)

          -  Patient over 18 years old

          -  Signed informed consent

        Exclusion Criteria:

          -  Patients at high risk of breast cancer, mutations BRCA 1 (BReast CAncer gene 1) or
             BRCA 2 (BReast CAncer gene 2) carriers, Li Fraumeni, or history of thoracic radiation
             will be excluded because of their greater sensitivity to ionizing radiation.

          -  Patient unable to give informed consent for physical, mental, or legal reasons.

          -  Patient not affiliated with French Social Security Insurance.

          -  Patient under treatment for breast cancer.

          -  When mammography is not recommended according to good practice by the French Health
             Authority (HAS).

          -  Pregnant patient.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>cedric De Bazelaire, MD PHD</last_name>
    <phone>142499133</phone>
    <phone_ext>+33</phone_ext>
    <email>cedric.de-bazelaire@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthieu Resche-Rigon, MD PHD</last_name>
    <phone>142499742</phone>
    <phone_ext>+33</phone_ext>
    <email>matthieu.resche-rigon@univ-paris-diderot.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>matthieu resche-rigon</last_name>
      <phone>142499742</phone>
      <phone_ext>+33</phone_ext>
      <email>matthieu.resche-rigon@univ-paris-diderot.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle THOMASSIN- NAGGARA, Pr</last_name>
      <email>isabelle.thomassin@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2016</study_first_submitted>
  <study_first_submitted_qc>November 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2016</study_first_posted>
  <last_update_submitted>November 22, 2017</last_update_submitted>
  <last_update_submitted_qc>November 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

